Evidence map›Paper›PMID 37798372›Full record

ArticleBritish journal of cancer2023

ACAA2 is a novel molecular indicator for cancers with neuroendocrine phenotype.

Michelle Shen, Shiqin Liu, Angus Toland, En-Chi Hsu, Alifiani B Hartono, Busola R Alabi, Merve Aslan, Holly M Nguyen, Conner J Sessions, Rosalie Nolley and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Michelle ShenDepartment of Radiology, Stanford University, Stanford, CA, USA.
Shiqin LiuDepartment of Radiology, Stanford University, Stanford, CA, USA.
Angus TolandDepartment of Pathology, Stanford University, Stanford, CA, USA.
En-Chi HsuDepartment of Radiology, Stanford University, Stanford, CA, USA.
Alifiani B HartonoDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA.
Busola R AlabiDepartment of Radiology, Stanford University, Stanford, CA, USA.
Merve AslanDepartment of Radiology, Stanford University, Stanford, CA, USA.
Holly M NguyenDepartment of Urology, University of Washington, Seattle, WA, USA.
Conner J SessionsDepartment of Urology, University of Washington, Seattle, WA, USA.
Rosalie NolleyDepartment of Urology, Stanford University, Stanford, CA, USA.
Chanjuan ShiDepartment of Pathology, Duke University, Durham, NC, USA.
Jiaoti HuangDepartment of Pathology, Duke University, Durham, NC, USA.ORCID 0000-0003-1195-1998
James D BrooksCanary Center at Stanford for Cancer Early Detection, Stanford University, Stanford, CA, USA.
Eva CoreyDepartment of Urology, University of Washington, Seattle, WA, USA.ORCID 0000-0002-9244-3807
Tanya StoyanovaDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA. tstoyanova@mednet.ucla.edu.
Stanford University · USUniversity of California, Los Angeles · USUniversity of Washington · USDuke University · US

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PETER S NELSON · 2013 to 2026
$25.0M
Stanford Molecular and Cellular Characterization LaboratoryU01CA196387 · NCI · STANFORD UNIVERSITY · PI BROOKS, JAMES D. · 2015 to 2020
$5.2M
Elucidating the Role of Trop2 in Prostate CancerR37CA240822 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tanya I Stoyanova · 2020 to 2026
$2.5M
Delineate the Role of GSTP1 in Advanced Prostate CancerR01CA274978 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Tanya I Stoyanova · 2023 to 2026
$1.8M
Elucidating the Role of UCHL1 in Aggressive Prostate CancerR01CA244281 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI STOYANOVA, TANYA I · 2020 to 2024
$1.8M
DESI-MS detection of positive margins in kidney cancerR21CA229933 · NCI · STANFORD UNIVERSITY · PI BROOKS, JAMES D., ZARE, RICHARD N · 2018 to 2019
$369k
NCI NIH HHS P01 CA163227NCI NIH HHS P50 CA092131NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA244281NCI NIH HHS R01 CA274978NCI NIH HHS R21 CA229933NCI NIH HHS R37 CA240822NCI NIH HHS U01 CA196387
6 · The paper itself

Abstract

backgroundNeuroendocrine phenotype is commonly associated with therapy resistance and poor prognoses in small-cell neuroendocrine cancers (SCNCs), such as neuroendocrine prostate cancer (NEPC) and small-cell lung cancer (SCLC). Expression levels of current neuroendocrine markers exhibit high case-by-case variability, so multiple markers are used in combination to identify SCNCs. Here, we report that ACAA2 is elevated in SCNCs and is a potential molecular indicator for SCNCs.

methodsACAA2 expressions in tumour xenografts, tissue microarrays (TMAs), and patient tissues from prostate and lung cancers were analysed via immunohistochemistry. ACAA2 mRNA levels in lung and prostate cancer (PC) patients were assessed in published datasets.

resultsACAA2 protein and mRNA levels were elevated in SCNCs relative to non-SCNCs. Medium/high ACAA2 intensity was observed in 78% of NEPC PDXs samples (N = 27) relative to 33% of adeno-CRPC (N = 86), 2% of localised PC (N = 50), and 0% of benign prostate specimens (N = 101). ACAA2 was also elevated in lung cancer patient tissues with neuroendocrine phenotype. 83% of lung carcinoid tissues (N = 12) and 90% of SCLC tissues (N = 10) exhibited medium/high intensity relative to 40% of lung adenocarcinoma (N = 15).

conclusionACAA2 expression is elevated in aggressive SCNCs such as NEPC and SCLC, suggesting it is a potential molecular indicator for SCNCs.

Indexed as

Carcinoma, NeuroendocrineCarcinoma, Small CellLung NeoplasmsProstatic NeoplasmsSmall Cell Lung CarcinomaAcetyl-CoA C-AcyltransferaseCell Line, TumorHumansMalePhenotypeRNA, MessengerACAA2 protein, humanAcetyl-CoA C-AcyltransferaseRNA, Messenger

Identifiers

PMID37798372
PMCPMC10667239
OpenAlexW4387389393

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.